Arizona Lithium (ASX:AZL) Receives Approval for Phase 1 Production at Prairie Project
Arizona Lithium (ASX:AZL) secures Phase 1 production approval for Prairie Project, enhancing resource estimates and marking a first in Saskatchewan.
Tag: Industry-Specific News
Urbanise.com Ltd (ASX:UBN) Announces Strategic Partnership with NAB
Urbanise.com Ltd (ASX:UBN) partners with NAB to integrate payment solutions and secure a strategic equity stake.
Diablo Resources (ASX:DBO) Identifies New Copper Targets in Phoenix Project
Diablo Resources (ASX:DBO) identifies four high-priority copper targets in Utah’s Phoenix Project, planning drilling in Q3 2025.
Askari Metals (ASX:AS2) Announces Options Priority Offer and African Expansion Plans
Askari Metals (ASX:AS2) offers new options to expired holders and advances its African expansion with a potential gold project acquisition in Ethiopia.
Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant symptom relief trends.
Streamplay Studio (ASX:SP8) Expands Cloud Gaming to Sri Lanka
Streamplay Studio (ASX:SP8) partners with Mobibox to launch Playstream cloud gaming service exclusively for Sri Lanka’s largest mobile operator.
Simble Solutions Limited (ASX:SIS) Announces 2024 Operational Highlights and Strategic Partnerships
Simble Solutions Limited (ASX:SIS) reports significant 2024 operational achievements and strategic partnerships, driving growth and expansion.
Hastings Technology Metals (ASX:HAS) Forms Joint Venture with Wyloo
Hastings Technology Metals (ASX:HAS) forms a 60:40 joint venture with Wyloo for the Yangibana Project, advancing development and reducing costs.
Tempest Minerals Limited (ASX:TEM) Reports Excellent Metallurgical Results for Remorse Deposit
Tempest Minerals Limited (ASX:TEM) reports excellent initial metallurgical results for the Remorse Deposit at Yalgoo Project.
Chimeric Therapeutics (ASX:CHM) Reports Positive ADVENT-AML Trial Results
Chimeric Therapeutics (ASX:CHM) reports that two of three patients achieved complete response in its ADVENT-AML Phase 1B clinical trial.